Cerus reported first‑quarter 2026 results that included total revenue of $59.9 million and product revenue of $53.7 million, a net loss of $1.6 million, and a GAAP earnings‑per‑share of $0.01. The company beat analyst expectations, with revenue exceeding the consensus range of $53.17 million to $56.17 million by $3.7 million and EPS surpassing the $0.03 to $0.04 estimate by $0.02 to $0.03.
Revenue growth was driven by a 120 % year‑over‑year increase in INTERCEPT Fibrinogen Complex (IFC) sales, which rose to $5.7 million in the quarter from $3.0 million in Q1 2025. North America accounted for roughly 70 % of product revenue, and the global platelet franchise continued to provide a solid foundation for the company’s top‑line momentum.
Product gross margin fell to 52.0 % in Q1 2026 from 58.8 % in Q1 2025. Management attributed the decline to the loss of a prior‑year one‑time benefit, inflationary pressures, unfavorable foreign‑currency movements, and tariff impacts, all of which have compressed margins despite the stronger product mix.
In light of the results, Cerus raised its full‑year 2026 product‑revenue guidance to $227 million to $231 million, up from the previous $224 million to $228 million range. The company also increased its IFC revenue guidance to $22 million to $24 million. “We are raising our full‑year 2026 product revenue guidance to $227 million to $231 million and raising full‑year IFC revenue guidance to $22 million to $24 million,” said incoming President and CEO Vivek Jayaraman. “This reflects total year‑over‑year product revenue growth of 10 % to 12 % compared to 2025 and approximately 30 % to 40 % for IFC.”
CFO Kevin Green noted that Cerus expects 2026 to be its third consecutive year of positive adjusted EBITDA and reiterated the company’s commitment to achieving GAAP profitability. The leadership transition, with Jayaraman taking the helm on July 1 2026, signals continuity in strategy while positioning the company for continued growth.
The earnings beat, guidance upgrade, and strong IFC demand underscore Cerus’s improving operational efficiency and market traction. While margin compression highlights current headwinds, the company’s focus on high‑margin platelet and IFC products, coupled with a robust cash position of $80.4 million, supports a positive outlook for the remainder of the year.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.